CN1459287A - Cytophosphocholine sodium quantitative drop - Google Patents
Cytophosphocholine sodium quantitative drop Download PDFInfo
- Publication number
- CN1459287A CN1459287A CN 02110455 CN02110455A CN1459287A CN 1459287 A CN1459287 A CN 1459287A CN 02110455 CN02110455 CN 02110455 CN 02110455 A CN02110455 A CN 02110455A CN 1459287 A CN1459287 A CN 1459287A
- Authority
- CN
- China
- Prior art keywords
- quantitative drop
- sodium
- cytophosphocholine
- quantitative
- drop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A quantitative drop of citicoline sodium is prepared from citicoline sodium as medicinal raw material and a certain assistant through compounding into a solution. It is applied by use of a quantitative drip pump and a jet tube to directly jet it into oral cavity. Its advantages are easy absorption, no by-effect, currect dosage, and agreeable taste.
Description
Technical field:
The present invention relates to medicine, is a kind of Cytophosphocholine sodium quantitative drop.
Background technology:
C14H25N4NaO11P2 is a central stimulants, to improving brain tissue metabolism, promotes the brain function recovery to promote to revive that certain effect is arranged.Be mainly used in the postoperative disturbance of consciousness of acute craniocerebral trauma and brain.C14H25N4NaO11P2 has injection and two kinds of dosage forms of oral liquid, and pharmacokinetic study shows no matter inject or oral administration, and it can enter the brain metabolism equally, produce phospholipid turn into and come into force.Zoopery shows that intravenously administrable can absorb fully very soon, oral then absorption fully lentamente, and both act on no significant difference.Oral administration can be avoided destructive stimulus, increases the animals survived time under the hypoxia.The common side effect of injection administration is one to cross property hypotension and parasympathetic nervous reaction, and does not orally find side effect.Oral C14H25N4NaO11P2 is to dizziness, headache, insomnia, hypomnesis, absent minded etc. evident in efficacy; To instability of gait, muscular strength go down, aphasis is comparatively satisfied.And side effect is slight, does not have the side effect of the injection that bibliographical information occurs.
Summary of the invention:
The objective of the invention is, a kind of Cytophosphocholine sodium quantitative drop is provided, on the basis of C14H25N4NaO11P2 oral liquid, we adopt foreign technology to use the quantitative drop pump of keeping a public place clean, and are to press taking convenience with every 1ml, accurate measurement solves dosage and hygienic issues simultaneously.Keep C14H25N4NaO11P2 oral liquid determined curative effect simultaneously, absorbed fully bioavailability height, the advantage that side effect is low.
The present invention is in order to solve the existing in prior technology problem, adopt following scheme to solve, Cytophosphocholine sodium quantitative drop comprises that C14H25N4NaO11P2 medicine material and correctives, antiseptic, aqueous solvent etc. are formulated, and adopt the quantitative drop pump, by mechanical force pressing valve medicinal liquid is quantitatively pumped.The ratio of C14H25N4NaO11P2 principal agent raw material in this preparation is: 10～500mg/ml, correctives stevioside and the citric acid ratio in this preparation is 0.25～3mg/ml and 1～10mg/ml.The ratio of preservative sodium benzoate in this preparation is 0.1～5mg/ml.The amount of liquid that quantitative drop is whenever pressed is 0.25～2ml.Each 1～the 2ml of adult's medication, every day 2～3 times.The ratio of C14H25N4NaO11P2 principal agent raw material in this preparation can be 100mg/ml, and correctives stevioside and the citric acid ratio in this preparation is 1.5mg/ml and 5mg/ml.The ratio of preservative sodium benzoate in this preparation is 1mg/ml.Each 1～the 2ml of adult's medication, every day 2～3 times.Cytophosphocholine sodium quantitative drop medicine material component and content are:
C14H25N4NaO11P2 10～500mg
Stevioside 0.25～3mg
Citric acid 1～10mg
Sodium benzoate 0.1～5mg
Water 1ml
The amount of liquid that quantitative drop is whenever pressed is 0.25～2ml.Each 1～the 2ml of adult's medication, every day 2～3 times.
Cytophosphocholine sodium quantitative drop medicine material component and content can be:
C14H25N4NaO11P2 100mg
Stevioside 1.5mg
Citric acid 5mg
Sodium benzoate 1mg
Water 1ml
The amount of liquid that quantitative drop is whenever pressed is 1.0ml.Each 1～the 2ml of adult's medication, every day 2～3 times.
Medicine of the present invention proves that through pharmacological testing it has common C14H25N4NaO11P2 oral liquid determined curative effect, absorbs fully, the bioavailability height, the advantage that side effect is low, quantitative drop adopts the quantitative drop pump simultaneously, the dosage accurate science is reasonable, has avoided leaning on clinically the shortcoming of experience administration.Quantitative drop adopts jet pipe, direct entry portal intracavity, and administration is very convenient.Mouthfeel is good, is easy to accept.Solve dosage and hygienic issues simultaneously.
The specific embodiment:
It comprises that C14H25N4NaO11P2 medicine material and certain adjuvant etc. are mixed with solution, and adopts the quantitative drop pump, by mechanical force pressing valve medicinal liquid is quantitatively pumped.The concentration of principal agent raw material C14H25N4NaO11P2 in this preparation is 10～500mg/ml.The amount of liquid that quantitative drop is whenever pressed is 0.25～2ml.Each 1～the 2ml of adult's medication, every day 2～3 times.
Cytophosphocholine sodium quantitative drop medicine material component and content are:
C14H25N4NaO11P2 10～500mg
Stevioside 0.25～3mg
Citric acid 1～10mg
Sodium benzoate 0.1～5mg
Water 1ml
The amount of liquid that quantitative drop is whenever pressed is 0.25～2ml.Each 1～the 2ml of adult's medication, every day 2～3 times.
Cytophosphocholine sodium quantitative drop medicine material component and content can be:
C14H25N4NaO11P2 100mg
Stevioside 1.5mg
Citric acid 5mg
Sodium benzoate 1mg
Water 1ml
The amount of liquid that quantitative drop is whenever pressed is 0.5ml.Each 1～the 2ml of adult's medication, every day 2～3 times.
The preparation technology of Cytophosphocholine sodium quantitative drop of the present invention is as follows:
Take by weighing C14H25N4NaO11P2, stevioside, citric acid and the sodium benzoate of recipe quantity, complete with deionized water dissolving, be settled to 1ml, stir.Filter, after the passed examination, fill screws on the bottle cap of band proportional valve in vial.Packing promptly.
Various components contents of the present invention is the content of making 1ml quantitative drop of the present invention.
Claims (4)
1, Cytophosphocholine sodium quantitative drop is characterized in that: 1) it comprises that C14H25N4NaO11P2 medicine material and certain adjuvant etc. are mixed with solution, and adopts the quantitative drop pump, by mechanical force pressing valve medicinal liquid is quantitatively pumped.2) concentration of principal agent raw material C14H25N4NaO11P2 in this preparation is 10～500mg/ml.3) amount of liquid whenever pressed of quantitative drop is 0.25～2ml.Each 1～the 2ml of adult's medication, every day 2～3 times.
2, according to claims 1 described Cytophosphocholine sodium quantitative drop, it is characterized in that: 1) concentration of principal agent raw material C14H25N4NaO11P2 in this preparation is that 10～500mg/ml2) correctives steviosides and the ratio of citric acid in this preparation are 0.25～3mg/ml and 1～10mg/ml, and the correctives that can be used for this preparation has stevioside, saccharin sodium, aspartame, sucrose, xylitol, maltose, fructose, citric acid.The ratio of preservative sodium benzoate in this preparation is 0.1～5mg/ml, and the antiseptic that can be used for this preparation has benzoic acid, sodium benzoate, methyl hydroxybenzoate, ethyl hydroxybenzoate, sorbic acid.3) amount of liquid whenever pressed of quantitative drop is 0.25～2ml.
3, according to claims 1 described Cytophosphocholine sodium quantitative drop, it is characterized in that:
1) Cytophosphocholine sodium quantitative drop medicine material component and content are:
C14H25N4NaO11P2 10～500mg
Stevioside 0.25～3mg
Citric acid 1～10mg
Sodium benzoate 0.1～5mg
Water 1ml
2) quantitative drop adopts the quantitative drop pump, by mechanical force pressing valve medicinal liquid is quantitatively pumped.
3) amount of liquid whenever pressed of quantitative drop is 0.25～2ml.Each 1～the 2ml of adult's medication, every day 2～3 times.
4, Cytophosphocholine sodium quantitative drop according to claim 1 and 2 is characterized in that: 1) Cytophosphocholine sodium quantitative drop medicine material component and content are:
C14H25N4NaO11P2 100mg
Stevioside 1.5mg
Citric acid 5mg
Sodium benzoate 1mg
Water 1ml
2) quantitative drop adopts the quantitative drop pump, by mechanical force pressing valve medicinal liquid is quantitatively pumped.
3) amount of liquid of whenever pressing is 1ml.Each 1～the 2ml of adult's medication, every day 2～3 times.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02110455 CN1459287A (en) | 2002-05-24 | 2002-05-24 | Cytophosphocholine sodium quantitative drop |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02110455 CN1459287A (en) | 2002-05-24 | 2002-05-24 | Cytophosphocholine sodium quantitative drop |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1459287A true CN1459287A (en) | 2003-12-03 |
Family
ID=29426316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02110455 Pending CN1459287A (en) | 2002-05-24 | 2002-05-24 | Cytophosphocholine sodium quantitative drop |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1459287A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491522A (en) * | 2016-09-24 | 2017-03-15 | 北京万全德众医药生物技术有限公司 | A kind of levo-cetirizine hydrochloride Oral drops and preparation method thereof |
-
2002
- 2002-05-24 CN CN 02110455 patent/CN1459287A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491522A (en) * | 2016-09-24 | 2017-03-15 | 北京万全德众医药生物技术有限公司 | A kind of levo-cetirizine hydrochloride Oral drops and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gancher et al. | Absorption of apomorphine by various routes in parkinsonism | |
| CN1917883A (en) | Use of treprostinil to improve kidney functions | |
| WO2000038672A2 (en) | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy | |
| CN1171740A (en) | Oral compositions containing ondansetron | |
| CN110279695B (en) | A pharmaceutical composition for treating common cold with symptoms of watery nasal discharge and nasal obstruction, and its preparation method and application | |
| Djaldetti et al. | Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease | |
| CN1459287A (en) | Cytophosphocholine sodium quantitative drop | |
| US20040101563A1 (en) | Storage stable antihistaminic syrup formulations | |
| CN1279897C (en) | Freeze dry preparation containing diclofenac salt and lidocaine and its preparation method | |
| US20090028802A1 (en) | Organoleptically acceptable indole serotonin receptor agonist oral dosage formulations and methods of using the same | |
| Campbell et al. | Stability of amiodarone hydrochloride in admixtures with other injectable drugs | |
| RU2005125633A (en) | METHOD FOR PRODUCING INJECTIONAL MEDICINAL FORM OF PHOSPHOLIPID DRUG "PHOSFOGLIV" FOR TREATMENT AND PREVENTION OF ACUTE AND CHRONIC DISEASES OF THE LIVER | |
| US20110195988A1 (en) | Pharmaceutical Composition | |
| US11801236B2 (en) | Pramipexole hydrochloride oral liquid | |
| CN1195517C (en) | Rationed fenmameimin drops | |
| US20220339124A1 (en) | Intranasal pharmaceutical compositions of cyclobenzaprine | |
| US7008927B2 (en) | Pralmorelin-containing nasal drop preparations | |
| CN1850097A (en) | Scutellarin injection preparation and its preparing method | |
| CN1895269A (en) | Compound iodine oral solution quantitative drops and preparation thereof | |
| CN115715758B (en) | Phloroglucinol oral liquid and production method thereof | |
| RU2783438C1 (en) | Anesthetic liquid pharmaceutical composition | |
| CN1206989C (en) | Mixed snuff prepn. for reducing side effect of Apomorphinum | |
| CN1788728A (en) | Compound oral liquid and suspensoid containing brufen for treating cold | |
| CN105816432B (en) | Freeze-dried ropivacaine hydrochloride composition for injection and quality control method thereof | |
| ES2363395B1 (en) | PHARMACEUTICAL COMPOSITION L�? QUIDA DE RIVASTIGMINA OR ONE OF ITS ADDITION SALES OF �? CIDO FOR ADMINISTRATION BY ORAL. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |